Eli Lilly’s Dan Skovronsky on oral GLP-1, ‘slower ramp’ for Alzheimer’s and deals on ‘underappreciated’ assetsnews2023-11-29T12:11:57+00:00November 29th, 2023|Endpoints News|
FDA to make decision about Karuna’s schizophrenia drug by next Septembernews2023-11-29T11:30:06+00:00November 29th, 2023|Endpoints News|
Amgen teams up with Amazon on AI platform to enhance new Ohio manufacturing sitenews2023-11-29T11:00:19+00:00November 29th, 2023|Endpoints News|
Big Pharma unites to help boost renewable energy for supply chains in China and Indianews2023-11-29T07:00:19+00:00November 29th, 2023|Endpoints News|
Illumina CFO says there’s outside interest in Grail as ‘outright sale’ explorednews2023-11-28T19:59:42+00:00November 28th, 2023|Endpoints News|
FDA opens review of CAR-T safety after identifying 19 cases of post-treatment blood cancernews2023-11-28T19:54:32+00:00November 28th, 2023|Endpoints News|
Harvard scholars call to eliminate orphan drug exemption in IRA to save Medicare morenews2023-11-28T19:51:24+00:00November 28th, 2023|Endpoints News|
BioMarin lands three-year deal for German coverage of gene therapy at $900K per patientnews2023-11-28T18:49:57+00:00November 28th, 2023|Endpoints News|
MarketingRx roundup: Pfizer adds holiday twist to Covid booster effort; Novavax signs up for sportsnews2023-11-28T17:36:04+00:00November 28th, 2023|Endpoints News|
Immunovant plans multiple trials for FcRn inhibitor based on PhI data to compete with argenx, J&Jnews2023-11-28T16:37:00+00:00November 28th, 2023|Endpoints News|
